A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies
Checked against the public recordLast updated May 27, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- AstraZeneca
- Interventions being studied
- Drug: AZD6244; Drug: Dacarbazine; Drug: Erlotinib; Drug: Docetaxel; Drug: Temsirolimus
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status 0-1 * Patients must be able to swallow AZD6244 capsules Exclusion Criteria: * Prior treatment with a MEK inhibitor * Participation in a clinical study during the last 30 days or have not recovered from side effects of an investigational study drug * Brain metastases or spinal cord compression unless treated and stable (for at least 1 month) off steroids
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteDetroit, Michigan
- Research SitePhiladelphia, Pennsylvania
- Research SiteNashville, Tennessee
- Research SiteHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 27, 2026. Always confirm current availability with the study team.